Question 1

What is Alpha Antitrypsin Deficiency?

Accepted Answer

Alpha Antitrypsin Deficiency occurs when the body is unable to produce sufficient amounts of Alpha Antitrypsin protein, exposing the organs to harmful effects of proteolytic enzymes, such as neutrophil elastase. Alpha Antitrypsin protein, a protein made in the liver, plays an important role in protecting organs of the body such lungs from proteolytic enzymes, but some causes lead the protein to be unable to enter the bloodstream and work as desired, leading to increased risk of lung disease. Read More

Question 2

How is epidemiology segmented for Alpha Antitrypsin Deficiency?

Accepted Answer

The total prevalent population of Alpha Antitrypsin Deficiency, total diagnosed population of Alpha Antitrypsin Deficiency, genotype of Alpha Antitrypsin Deficiency diagnosed pool and comorbidities associated with Alpha Antitrypsin Deficiency. Read More

Question 3

What was the Alpha Antitrypsin Deficiency total prevalent cases in 2017?

Accepted Answer

The total number of prevalent cases of Alpha Antitrypsin Deficiency in 6 MM was found to be 175,009 in the year 2017. Read More

Question 4

What was the Alpha Antitrypsin Deficiency market in 2017?

Accepted Answer

The market of Alpha Antitrypsin Deficiency in 6MM was found to be USD 698 Million in 2017. Read More

Question 5

Which companies are developing drugs for Alpha Antitrypsin Deficiency?

Accepted Answer

Kamada Ltd, Alnylam Pharmaceuticals, Arrow Head Pharmaceuticals, Vertex Pharmaceuticals, Mereo Biopharma, Dicerna Pharmaceuticals are developing drugs for Alpha Antitrypsin Deficiency. Read More